CREDENCE: Type 2 diabetes management – a new perspective (Promotional content from Napp Pharmaceuticals Limited) | GPnotebook TV

This site is intended for UK healthcare professionals

This promotional video was developed by Napp Pharmaceuticals Limited and Napp products are discussed. Napp fully funded the video and is responsible for the content, logistics and selection of speakers. OmniaMed provided editorial, marketing and logistical support.

Click for prescribing information for Invokana® (canagliflozin)

CREDENCE: Type 2 diabetes management – a new perspective (Promotional content from Napp Pharmaceuticals Limited)

22 July 2020

Sponsored

During this hour-long broadcast, Dr Kevin Fernando, Professor David Wheeler and Dr Amrit Lamba consider the recent license extension to Invokana® (canagliflozin) and how this could change the management of diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) in primary care.

With translation to primary care being very much at the heart of the agenda, we also take a detailed look at kidney function, kidney function assessment, and interpreting the results of common tests. This video was originally broadcast on 22 July 2020.

The video is divided into the following chapters (to navigate between chapters, use the blue dots on the video timeline bar):

  • 00:00 Chair’s introduction: Current management of DKD in T2DM (Dr Kevin Fernando, GP Partner, North Berwick Health Centre; GPwSI in Diabetes & Medical Education)
  • 08:15 Bringing CREDENCE to life: What does the data show? (Professor David Wheeler Honorary Consultant Nephrologist and Professor of Kidney Medicine, Royal Free, London)
  • 24:26 Management of DKD in T2DM – past, present and future: CREDENCE in context (Dr Amrit Lamba, GPwSI in Diabetes; Partner, Colindale Medical Centre, London)
Napp logo Diabetes

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk.

Date of preparation: August 2020    UK/INV-20106aa

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

This website is for healthcare professionals

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional by clicking the ‘Confirm’ button below.

We use anonymous cookies to generate usage statistics. Please click here to find out more.